{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T10:06:09Z","timestamp":1776765969980,"version":"3.51.2"},"reference-count":67,"publisher":"Elsevier","isbn-type":[{"value":"9780443313585","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["AI05509"],"award-info":[{"award-number":["AI05509"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["MH084512"],"award-info":[{"award-number":["MH084512"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["AI074654"],"award-info":[{"award-number":["AI074654"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.apha.2024.10.003","type":"book-chapter","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T12:49:04Z","timestamp":1729082944000},"page":"183-202","source":"Crossref","is-referenced-by-count":2,"title":["The discovery and development of the sphingosine 1-phosphate receptor modulator ozanimod in ulcerative colitis"],"prefix":"10.1016","member":"78","reference":[{"issue":"5","key":"10.1016\/bs.apha.2024.10.003_bib1","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.cgh.2023.11.018","article-title":"Cardiovascular safety of ozanimod in patients with ulcerative colitis: True north and open-label extension analyses","volume":"22","author":"Armuzzi","year":"2024","journal-title":"Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association"},{"issue":"6051","key":"10.1016\/bs.apha.2024.10.003_bib2","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1126\/science.1208248","article-title":"GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood","volume":"333","author":"Arnon","year":"2011","journal-title":"Science (New York, N. Y.)"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.003_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051498","article-title":"Downregulation of the S1P transporter spinster homology protein 2 (Spns2) exerts an anti-fibrotic and anti-inflammatory effect in human renal proximal tubular epithelial cells","volume":"19","author":"Blanchard","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.003_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/jcph.244","article-title":"Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: Favorable impact of dose up-titration","volume":"54","author":"Brossard","year":"2014","journal-title":"Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.003_bib5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/mol.112.082958","article-title":"Sphingosine 1-phosphate receptor 1 (S1P(1)) upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P(1) antagonist","volume":"83","author":"Cahalan","year":"2013","journal-title":"Molecular Pharmacology"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.003_bib6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nchembio.547","article-title":"Actions of a picomolar short-acting S1P(1) agonist in S1P(1)-eGFP knock-in mice","volume":"7","author":"Cahalan","year":"2011","journal-title":"Nature Chemical Biology"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.003_bib7","first-page":"1056","article-title":"FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats","volume":"28","author":"Chiba","year":"1996","journal-title":"Transplantation Proceedings"},{"issue":"1-2","key":"10.1016\/bs.apha.2024.10.003_bib8","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0041-1345(98)01975-7","article-title":"FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing","volume":"31","author":"Chiba","year":"1999","journal-title":"Transplantation Proceedings"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.003_bib9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1474-4422(16)00018-1","article-title":"Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): A randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Cohen","year":"2016","journal-title":"Lancet Neurology"},{"issue":"11","key":"10.1016\/bs.apha.2024.10.003_bib10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): A multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurology"},{"issue":"11","key":"10.1016\/bs.apha.2024.10.003_bib11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): A multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurology"},{"issue":"12","key":"10.1016\/bs.apha.2024.10.003_bib12","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1177\/13524585221102584","article-title":"Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial","volume":"28","author":"Cree","year":"2022","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.003_bib13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/ecco-jcc\/jjad146","article-title":"Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: Interim analysis of the true north open-label extension","volume":"18","author":"Danese","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/bs.apha.2024.10.003_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102673","article-title":"Effect of ozanimod on symbol digit modalities test performance in relapsing MS","volume":"48","author":"DeLuca","year":"2021","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"21","key":"10.1016\/bs.apha.2024.10.003_bib15","doi-asserted-by":"crossref","first-page":"15833","DOI":"10.1074\/jbc.M609124200","article-title":"Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues","volume":"282","author":"Don","year":"2007","journal-title":"Journal of Biological Chemistry"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.003_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ab.2007.12.024","article-title":"A fluorescent plate reader assay for ceramide kinase","volume":"375","author":"Don","year":"2008","journal-title":"Analytical Biochemistry"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.003_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbrc.2009.01.075","article-title":"A lipid binding domain in sphingosine kinase 2","volume":"380","author":"Don","year":"2009","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"12","key":"10.1016\/bs.apha.2024.10.003_bib18","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1096\/fj.15-274936","article-title":"Spinster 2, a sphingosine-1-phosphate transporter, plays a critical role in inflammatory and autoimmune diseases","volume":"29","author":"Donoviel","year":"2015","journal-title":"The FASEB Journal"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.003_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01200143","article-title":"Nobel lecture. G proteins and regulation of adenylyl cyclase","volume":"15","author":"Gilman","year":"1995","journal-title":"Bioscience Reports"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.003_bib20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1124\/mol.111.076109","article-title":"S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis","volume":"81","author":"Gonzalez-Cabrera","year":"2012","journal-title":"Molecular Pharmacology"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.003_bib21","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1124\/mol.108.049783","article-title":"Full pharmacological efficacy of a novel S1P(1) agonist that does not require S1P-like headgroup interactions","volume":"74","author":"Gonzalez-Cabrera","year":"2008","journal-title":"Molecular Pharmacology"},{"issue":"6070","key":"10.1016\/bs.apha.2024.10.003_bib22","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1126\/science.1215904","article-title":"Crystal structure of a lipid G protein-coupled receptor","volume":"335","author":"Hanson","year":"2012","journal-title":"Science (New York, N. Y.)"},{"issue":"12","key":"10.1016\/bs.apha.2024.10.003_bib23","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1021\/cb300392z","article-title":"Novel selective allosteric and bitopic ligands for the S1P(3) receptor","volume":"7","author":"Jo","year":"2012","journal-title":"ACS Chemical Biology"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.003_bib24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/mi.2016.35","article-title":"Sphingosine-1-phosphate receptor-1 (S1P(1)) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease","volume":"10","author":"Karuppuchamy","year":"2017","journal-title":"Mucosal Immunology"},{"issue":"25","key":"10.1016\/bs.apha.2024.10.003_bib25","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.1002\/anie.201302116","article-title":"The structural basis of G-protein-coupled receptor signaling (nobel lecture)","volume":"52","author":"Kobilka","year":"2013","journal-title":"Angewandte Chemie (International Ed. in English)"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.003_bib26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/nmt-2018-0012","article-title":"Phase III SUNBEAM and RADIANCE PART B trials for Ozanimod in relapsing multiple sclerosis demonstrate superiority versus interferon-beta-1a (Avonex(R)) in reducing annualized relapse rates and MRI brain lesions","volume":"8","author":"Koscielny","year":"2018","journal-title":"Neurodegenerative Disease Management"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.003_bib27","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-2125.2003.02065.x","article-title":"Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects","volume":"57","author":"Kovarik","year":"2004","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"8","key":"10.1016\/bs.apha.2024.10.003_bib28","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-020-01319-7","article-title":"Ozanimod: First approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.003_bib29","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cpdd.1379","article-title":"Safety, pharmacokinetics, and pharmacodynamics of etrasimod: Single and multiple ascending dose studies in healthy adults","volume":"13","author":"Lee","year":"2024","journal-title":"Clinical Pharmacology in Drug Development"},{"issue":"25","key":"10.1016\/bs.apha.2024.10.003_bib30","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1002\/anie.201301924","article-title":"A brief history of G-protein coupled receptors (Nobel Lecture)","volume":"52","author":"Lefkowitz","year":"2013","journal-title":"Angewandte Chemie (International Ed. in English)"},{"issue":"5566","key":"10.1016\/bs.apha.2024.10.003_bib31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.1070238","article-title":"Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists","volume":"296","author":"Mandala","year":"2002","journal-title":"Science (New York, N. Y.)"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.003_bib32","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013424","article-title":"Decreased serum level of sphingosine-1-phosphate: A novel predictor of clinical severity in COVID-19","volume":"13","author":"Marfia","year":"2021","journal-title":"EMBO Molecular Medicine"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.003_bib33","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1124\/mol.108.048769","article-title":"Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza","volume":"74","author":"Marsolais","year":"2008","journal-title":"Molecular Pharmacology"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.003_bib34","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1073\/pnas.0812689106","article-title":"A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection","volume":"106","author":"Marsolais","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apha.2024.10.003_bib35","first-page":"179","article-title":"Airway delivery of a sphingosine analog disrupts antigen presentation and inhibits virus-specific CD8(+)T cell expansion while sparing generation of protective antibodies after influenza virus infection","author":"Marsolais","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6972","key":"10.1016\/bs.apha.2024.10.003_bib36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2024.10.003_bib37","first-page":"129","article-title":"Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule","volume":"Vol. 378","author":"Oldstone","year":"2014"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.003_bib38","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.virol.2012.09.039","article-title":"Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection","volume":"435","author":"Oldstone","year":"2013","journal-title":"Virology"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.003_bib39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF01207453","article-title":"Nobel lecture. Signal transduction: Evolution of an idea","volume":"15","author":"Rodbell","year":"1995","journal-title":"Bioscience Reports"},{"key":"10.1016\/bs.apha.2024.10.003_bib40","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1146\/annurev.biochem.78.072407.103733","article-title":"Sphingosine 1-phosphate receptor signaling","volume":"78","author":"Rosen","year":"2009","journal-title":"Annual Review of Biochemistry"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.003_bib41","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013533","article-title":"The riddle of the Sphinx: Why sphingosine-1-phosphate may help define molecular mechanisms underlying risk stratification for serious COVID-19 infections","volume":"13","author":"Rosen","year":"2021","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/bs.apha.2024.10.003_bib42","first-page":"1","article-title":"The organization of the sphingosine 1-phosphate signaling system","volume":"Vol. 378","author":"Rosen","year":"2014"},{"key":"10.1016\/bs.apha.2024.10.003_bib43","first-page":"637","article-title":"Sphingosine-1-phosphate and its receptors: Structure, signaling, and influence","volume":"Vol. 82","author":"Rosen","year":"2013"},{"issue":"14","key":"10.1016\/bs.apha.2024.10.003_bib44","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1016\/bs.apha.2024.10.003_bib45","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","article-title":"Long-term efficacy and safety of ozanimod in moderately to severely active ulcerative colitis: Results from the open-label extension of the randomized, phase 2 TOUCHSTONE study","volume":"15","author":"Sandborn","year":"2021","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/bs.apha.2024.10.003_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2024.03.042","article-title":"Ozanimod in patients with moderate to severe ulcerative colitis naive to advanced therapies","author":"Sands","year":"2024","journal-title":"Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association"},{"issue":"14","key":"10.1016\/bs.apha.2024.10.003_bib47","doi-asserted-by":"crossref","first-page":"13839","DOI":"10.1074\/jbc.M311743200","article-title":"Sphingosine 1-phosphate (S1P) receptor subtypes S1P(1) and S1P(3), respectively, regulate lymphocyte recirculation and heart rate","volume":"279","author":"Sanna","year":"2004","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.003_bib48","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/mol.115.100222","article-title":"Bitopic sphingosine 1-phosphate receptor 3 (S1P3) antagonist rescue from complete heart block: Pharmacological and genetic evidence for direct S1P3 regulation of mouse cardiac conduction","volume":"89","author":"Sanna","year":"2016","journal-title":"Molecular Pharmacology"},{"issue":"8","key":"10.1016\/bs.apha.2024.10.003_bib49","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nchembio804","article-title":"Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P(1) antagonist in vivo","volume":"2","author":"Sanna","year":"2006","journal-title":"Nature Chemical Biology"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.003_bib50","first-page":"C1460","article-title":"Real-time differential labeling of blood, interstitium, and lymphatic and single-field analysis of vasculature dynamics in vivo","volume":"302","author":"Sarkisyan","year":"2012","journal-title":"American Journal of"},{"key":"10.1016\/bs.apha.2024.10.003_bib51","doi-asserted-by":"crossref","first-page":"32119","DOI":"10.1038\/srep32119","article-title":"Sphingosine kinase-1, S1P transporter spinster homolog 2 and S1P2 mRNA expressions are increased in liver with advanced fibrosis in human","volume":"6","author":"Sato","year":"2016","journal-title":"Scientific Reports"},{"issue":"8","key":"10.1016\/bs.apha.2024.10.003_bib52","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/cb800051m","article-title":"Ligand-binding pocket shape differences between sphingosine 1-phosphate (S1P) receptors S1P(1) and S1P(3) determine efficiency of chemical probe identification by ultrahigh-throughput screening","volume":"3","author":"Schurer","year":"2008","journal-title":"ACS Chemical Biology"},{"issue":"11","key":"10.1016\/bs.apha.2024.10.003_bib53","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P(1)) and receptor-5 (S1P(5)) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.003_bib54","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40265-024-01997-7","article-title":"Etrasimod: First approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/bs.apha.2024.10.003_bib55","article-title":"Inhibiting the inflammatory response following influenza virus infection utilizing sphingosine-1-phosphate receptor 1 signaling","volume":"184","author":"Teijaro","year":"2010","journal-title":"Journal of Immunology"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.003_bib56","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1073\/pnas.1525356113","article-title":"S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-alpha autoamplification","volume":"113","author":"Teijaro","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.003_bib57","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.cell.2011.08.015","article-title":"Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection","volume":"146","author":"Teijaro","year":"2011","journal-title":"Cell"},{"key":"10.1016\/bs.apha.2024.10.003_bib58","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.virol.2014.01.003","article-title":"Protection of ferrets from pulmonary injury due to H1N1 2009 influenza virus infection: Immunopathology tractable by Sphingosine-1-phosphate 1 receptor agonist therapy","volume":"452","author":"Teijaro","year":"2014","journal-title":"Virology"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.003_bib59","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1073\/pnas.1400593111","article-title":"Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection","volume":"111","author":"Teijaro","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.003_bib60","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/cpdd.383","article-title":"Cardiac safety of ozanimod, a novel sphingosine-1-phosphate receptor modulator: Results of a thorough QT\/QTc study","volume":"7","author":"Tran","year":"2018","journal-title":"Clinical Pharmacology in Drug Development"},{"key":"10.1016\/bs.apha.2024.10.003_bib61","article-title":"Pathogenic H1N1 2009 influenza virus-induced pulmonary injury is suppressed by sphingosine analog-mediated inhibition of cytokine storm","volume":"186","author":"Walsh","year":"2011","journal-title":"Journal of Immunology"},{"key":"10.1016\/bs.apha.2024.10.003_bib62","article-title":"Treatment with a sphingosine analog diminshes immunopathology following influenza virus infection","volume":"182","author":"Walsh","year":"2009","journal-title":"Journal of Immunology"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.003_bib63","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2009.08.043","article-title":"Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection","volume":"397","author":"Walsh","year":"2010","journal-title":"Virology"},{"issue":"11","key":"10.1016\/bs.apha.2024.10.003_bib64","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1128\/JVI.00464-14","article-title":"Animal model of respiratory syncytial virus: CD8(+) T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy","volume":"88","author":"Walsh","year":"2014","journal-title":"Journal of Virology"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.003_bib65","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12026-011-8240-z","article-title":"Quelling the storm: Utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm","volume":"51","author":"Walsh","year":"2011","journal-title":"Immunologic Research"},{"issue":"29","key":"10.1016\/bs.apha.2024.10.003_bib66","doi-asserted-by":"crossref","first-page":"12018","DOI":"10.1073\/pnas.1107024108","article-title":"Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus","volume":"108","author":"Walsh","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.003_bib67","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/ecco-jcc\/jjae007","article-title":"Achievement of clinical, endoscopic, and histological outcomes in patients with ulcerative colitis treated with etrasimod, and association with faecal calprotectin and C-reactive protein: Results from the phase 2 OASIS trial","volume":"18","author":"Yarur","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"}],"container-title":["Advances in Pharmacology","Emerging Therapeutic Targets and Drug Delivery Approaches in IBD"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358924000322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358924000322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T17:55:48Z","timestamp":1753293348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358924000322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443313585"],"references-count":67,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2024.10.003","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}